John Lee Villano, MD, PhD

Director, Clinical Neuro-Oncology Research Program

Clinical interests

  • Brain Tumors
  • Neuro-Oncology

John Lee Villano, MD, PhD

Director, Clinical Neuro-Oncology Research Program

Biography

My name is John L. Villano; I specialize in the treatment of brain cancers. I will advance UK HealthCare's Clinical Neuro-Oncology Research Program, serving as its director. UK HealthCare has a history of being a world-class neuro-oncology program, and I will help carry this tradition into the future.

Previously, I served as the director of medical neuro-oncology at the University of Illinois Medical Center. I earned a medical degree and doctor of philosophy at the University of Texas Southwestern Medical School at Dallas and trained in neurology at the University of Michigan. I also completed a fellowship in hematology/oncology at the University of Chicago. I am a former American Society of Clinical Oncology track leader for CNS tumors. Currently, I am on the board of the Central Brain Tumor Registry US. I am also a member of the Neuro-Oncology Committee in the cooperative group ALLIANCE and a Society of Neuro-Oncology committee member.

Faculty rank

Professor of Medicine

Education

Degree
University of Texas Southwestern Medical Center, Dallas

Residency
Neurology, University of Michigan Medical School, Ann Arbor
Internal Medicine, Cook County Hospital, Chicago

Fellowship
Hematology/Oncology, University of Chicago

Certifications or Special training
American Board of Internal Medicine
American Board of Internal Medicine, Medical Oncology

Brain Cancer

Multidisciplinary Clinic

Markey Cancer Center
Whitney-Hendrickson Building
First Floor
740 Rose St.
Lexington KY 40536-0098

HBCicon120x123
This is a clinic of the University of Kentucky Hospital, also known as UK Albert B. Chandler Hospital. Read more »



Medical Oncology

Multidisciplinary Clinic

Markey Cancer Center
Whitney-Hendrickson Building
Room 134
740 Rose St.
Lexington KY 40536-0098

Call 859-323-5275
Call 859-323-8043
Fax 859-257-3757

Directions to Markey Cancer Center - Whitney-Hendrickson Building »


UK HealthCare accepts many forms of insurance. See list of insurers »

 
  1. Gabay MP, Wirth SM, Stachnik JM, Overley CL, Long KE, Bressler LR, Villano JL. Oral Targeted Therapies and Central Nervous System (CNS) Metastases. CNS Drugs. 2015 Nov;29(11):935-52.
    View in: PubMed
  2. Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL. Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015 Jul 15;121(14):2400-10.
    View in: PubMed
  3. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96.
    View in: PubMed
  4. Villano JL, Williams LE, Watson KS, Ignatius N, Wilson MT, Valyi-Nagy T, Michals EA, Engelhard HH. Delayed response and survival from NovoTTF-100A in recurrent GBM. Med Oncol. 2013 Mar; 30(1):338. PMID: 23307238.
    View in: PubMed
  5. Popa AM, Valla K, Radhakrishnan L, Cuellar S, Villano JL. Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis. Ann Pharmacother. 2012 Nov; 46(11):e32. PMID: 23115228.
    View in: PubMed
  6. McCarthy BJ, Shibui S, Kayama T, Miyaoka E, Narita Y, Murakami M, Matsuda A, Matsuda T, Sobue T, Palis BE, Dolecek TA, Kruchko C, Engelhard HH, Villano JL. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro Oncol. 2012 Sep; 14(9):1194-200. PMID: 22869621.
    View in: PubMed
  7. Singh SK, Bansal VK, Wiley EL, Valyi-Nagy T, Villano JL. Long-term survival in an untreated patient with leptomeningeal carcinomatosis from breast primary. Clin Neurol Neurosurg. 2013 Mar; 115(3):362-4. PMID: 22727367.
    View in: PubMed
  8. Gabay MP, Thakkar JP, Stachnik JM, Woelich SK, Villano JL. Intra-CSF administration of chemotherapy medications. Cancer Chemother Pharmacol. 2012 Jul; 70(1):1-15. PMID: 22660736.
    View in: PubMed
  9. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep; 48(14):2192-202. PMID: 22608262.
    View in: PubMed
  10. Heery CR, Engelhard HH, Slavin KV, Michals EA, Villano JL. Unusual CNS presentation of thyroid cancer. Clin Neurol Neurosurg. 2012 Sep; 114(7):1107-9. PMID: 22296651.
    View in: PubMed
  11. Danciu OC, Rayani S, Michals EA, Villano JL. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med Oncol. 2012 Dec; 29(4):2619-22. PMID: 22209841.
    View in: PubMed
  12. Villano JL, Letarte N, Bressler LR. Going past the data for temozolomide. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1113-5. PMID: 22147076.
    View in: PubMed
  13. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12. PMID: 21984115.
    View in: PubMed
  14. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011 Oct 25; 105(9):1414-8. PMID: 21915121.
    View in: PubMed
  15. Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2012 Jan; 69(1):107-13. PMID: 21614470.
    View in: PubMed
  16. Bulj TK, Krunic AL, Cetner AS, Villano JL. Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib. Br J Dermatol. 2010 Sep; 163(3):633-7. PMID: 20222923.
    View in: PubMed
  17. Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB. Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine. 2010 Jul; 13(1):67-77. PMID: 20594020.
    View in: PubMed
  18. Bartram AH, Villano JL, Ferrera DM. Metastatic breast cancer mimicking hepatocellular carcinoma: differences in noninvasive guidelines. J Gastrointest Cancer. 2010 Jun; 41(2):145-8. PMID: 20084472.
    View in: PubMed
  19. Villano JL, Bressler L, Propp JM, Valyi-Nagy T, Martin IK, Dolecek TA, McCarthy BJ. Descriptive epidemiology of selected olfactory tumors. J Neurooncol. 2010 Oct; 100(1):73-80. PMID: 20151173.
    View in: PubMed
  20. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ. Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol. 2010 Mar; 12(3):257-64. PMID: 20167813.
    View in: PubMed
  21. Thulborn KR, Lu A, Atkinson IC, Damen F, Villano JL. Quantitative sodium MR imaging and sodium bioscales for the management of brain tumors. Neuroimaging Clin N Am. 2009 Nov; 19(4):615-24. PMID: 19959008.
    View in: PubMed
  22. Sharma AK, Fuller NJ, Sullivan RR, Fulton N, Hota PV, Harrington DA, Villano J, Hagerty JA, Cheng EY. Defined populations of bone marrow derived mesenchymal stem and endothelial progenitor cells for bladder regeneration. J Urol. 2009 Oct; 182(4 Suppl):1898-905. PMID: 19695585.
    View in: PubMed
  23. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009 Sep; 64(4):647-55. PMID: 19543728.
    View in: PubMed
  24. Villano JL, Mlinarevich N, Watson KS, Engelhard HH, Anderson-Shaw L. Aggression in a patient with primary brain tumor: ethical implications for best management. J Neurooncol. 2009 Sep; 94(2):293-6. PMID: 19267227.
    View in: PubMed
  25. Shord SS, Bressler LR, Radhakrishnan L, Chen N, Villano JL. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose. Ann Pharmacother. 2009 Feb; 43(2):235-41. PMID: 19193580.
    View in: PubMed
  26. James TC, Shaikh H, Escuadro L, Villano JL. Bilateral primary renal lymphoma. Br J Haematol. 2008 Oct; 143(1):1. PMID: 18513283.
    View in: PubMed
  27. Shord SS, Chew L, Villano J. Evaluation of opioid induced nausea and vomiting in sickle cell disease. Am J Hematol. 2008 Mar; 83(3):196-9. PMID: 17724690.
    View in: PubMed
  28. Villano JL, Propp JM, Porter KR, Stewart AK, Valyi-Nagy T, Li X, Engelhard HH, McCarthy BJ. Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro Oncol. 2008 Apr; 10(2):121-30. PMID: 18287340.
    View in: PubMed
  29. Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL. Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy. Onkologie. 2008 Mar; 31(3):119-21. PMID: 18322415.
    View in: PubMed
  30. Schellinger KA, Propp JM, Villano JL, McCarthy BJ. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008 Apr; 87(2):173-9. PMID: 18084720.
    View in: PubMed
  31. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug; 18(7):827-9. PMID: 17581306.
    View in: PubMed
  32. Villano JL, Mehta D, Radhakrishnan L. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs. 2006 Sep; 24(5):455-6. PMID: 16505953.
    View in: PubMed
  33. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51. PMID: 17409864.
    View in: PubMed
  34. Buckles GR, Rauskolb C, Villano JL, Katz FN. Four-jointed interacts with dachs, abelson and enabled and feeds back onto the Notch pathway to affect growth and segmentation in the Drosophila leg. Development. 2001 Sep; 128(18):3533-42. PMID: 11566858.
    View in: PubMed
  35. Villano JL, Katz FN. four-jointed is required for intermediate growth in the proximal-distal axis in Drosophila. Development. 1995 Sep; 121(9):2767-77. PMID: 7555705.
    View in: PubMed